LobbyingPharmacosmos Therapeutics lobbying by quarter
Pharmacosmos Therapeutics's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2024; the issues it reports most are Health Issues.
Pharmacosmos Therapeutics
- Latest quarter
- $0
- Q2 2026 · 1 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
Policy issues the reports name
- Health issues7 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES7 reports
- SENATE7 reports
Firms it paid
| Firm | ||
|---|---|---|
| Farragut Partners | $0 | 7 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CONSTANTINE HINGSON | Chief of Staff, Senator Dan Coats; Counsel/Legislative Director, Senator Judd Gregg; General Counsel, Senator Elizabeth Dole | Q2 2026 |
| DYLAN MOORE | Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) | Q2 2026 |
| EDWARD WHITFIELD | U.S. Representatives (21 yrs.) | Q2 2026 |
| JEFFERY C. MORTIER | Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes | Q2 2026 |
| JEFF MACKINNON | LD & LA Rep. Joe Barton (RTexas) | Q2 2026 |
| KRISTEN BAUTZ | Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz | Q2 2026 |
| SARAH WALTER | Former Legislative Director/Chief Counsel, Sen. John Breaux | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Farragut Partners | Under $5,000 |
| 04/20for Q1 | Farragut Partners | Under $5,000 |
| 01/20for Q4 2025 | Farragut Partners | Under $5,000 |
| 25/10/20for Q3 2025 | Farragut Partners | Under $5,000 |
| 25/07/21for Q2 2025 | Farragut Partners | Under $5,000 |
| 25/07/21for Q2 2025 | Farragut Partners | Under $5,000 |
| 25/04/21for Q1 2025 | Farragut Partners | Under $5,000 |
| 25/01/21for Q4 2024 | Farragut Partners | Under $5,000 |
| 25/01/16for Q4 2024 | Farragut Partners | Under $5,000 |